[ Network menu | Network entry | Help ]

ENTRY	nt06270
Name	Breast cancer
Category	Disease view; Cancer
Pathway	hsa05224 Breast cancer
Disease	H00031 Breast cancer
Display	drug-target relation   disease type

ERK signaling N00001    EGF → EGFR → GRB2 → SOS → RAS → RAF → MEK → ERK → CCND1 N00041        EGFR* → GRB2 → SOS → RAS → RAF → MEK → ERK N00021    EGF → (ERBB2+EGFR) → GRB2 → SOS → RAS → RAF → MEK → ERK       D5,D6,D7,D8,D9,D10,D11,D12  |                         N00022    EGF → (ERBB2*+EGFR) → GRB2 → SOS → RAS → RAF → MEK → ERK N00019    FGF → FGFR → GRB2 → SOS → RAS → RAF → MEK → ERK N00020        FGFR* → GRB2 → SOS → RAS → RAF → MEK → ERK PI3K signaling                   D1  |     N00033    EGF → EGFR → PI3K → PIP3 → AKT ⊣ BAD                   D1  |   D16  |     N00042        EGFR* → PI3K → PIP3 → AKT → MTOR → S6K       D5,D6,D7,D8,D9,D10,D11,D12  |           D1  |   D16  |     N00034    EGF → (ERBB2*+EGFR) → PI3K → PIP3 → AKT → MTOR → S6K                   D1  |   D16  |     N00037    FGF → FGFR → PI3K → PIP3 → AKT → MTOR → S6K                   D1  |   D16  | N00038        FGFR* → PI3K → PIP3 → AKT → MTOR           D18  |       D1  |   D16  |     N00049            PI3K* → PIP3 → AKT → MTOR → S6K                   D1  |   D16  |     N00050            PI3K* → PIP3 → AKT → MTOR → S6K                   D1  | N00220            PTEN ⊣ PIP3 → AKT                   D1  | N00052            PTEN* ⌿ PIP3 → AKT WNT signaling N00056    WNT → (FZD+LRP5/6) → (DVL+FRAT) ⊣ (GSK3B+AXIN+APC) ⊣ CTNNB1 → TCF/LEF ⇒ (MYC,CCND1) N00059    WNT → (FZD7*+LRP5/6) → (DVL+FRAT) ⊣ (GSK3B+AXIN+APC) ⊣ CTNNB1 → TCF/LEF ⇒ (MYC,CCND1) N00060    WNT → (FZD+LRP6*) → (DVL+FRAT) ⊣ (GSK3B+AXIN+APC) ⊣ CTNNB1 → TCF/LEF ⇒ (MYC,CCND1) NOTCH signaling N00086    (DLL,JAG) → NOTCH → (NICD+RBPJ) ⇒ (HES1,HEY1) N00087    (DLL,JAG) → (NOTCH1*,NOTCH4*) → (NICD+RBPJ) ⇒ (ERBB2,HES1,HES5,H.. Cell cycle                   D2,D3,D4  |         N00066    CDKN2A ⊣ MDM2 ⊣ TP53 ⇒ CDKN1A ⊣ (CCND+CDK4/6) → RB1 ⌿ E2F                   D2,D3,D4  |         N00275                    (CCND1*+CDK4) → RB1 ⌿ E2F Nuclear receptor signaling       D13,D14,D15  |   D17  | N00286    E2 → ((ESR1/2)+(NCOA1/2.. ⇒ (BCL2,EBAG9,KRT19,.. N00287    E2 → (ESR*+(NCOA3,NCOA1.. ⇒ (CCND1,MYC) Transcription N00115    TP53* ⌿ (CDKN1A,GADD45,BAX..

		Drug name
D1	D11371	Capivasertib (JAN/USAN)
D2	D10372	Palbociclib (JAN/USAN)
D3	D10688	Abemaciclib (JAN/USAN/INN)
D4	D10979	Ribociclib succinate (USAN)
D5	D03257	Trastuzumab (USAN/INN)
D6	D04024	Lapatinib ditosylate (USAN)
D7	D05446	Pertuzumab (USAN/INN)
D8	D09980	Trastuzumab emtansine (USAN/INN)
D9	D10446	Margetuximab (USAN/INN)
D10	D10898	Neratinib maleate
D11	D11141	Tucatinib (USAN/INN)
D12	D11529	Trastuzumab deruxtecan (USAN/INN)
D13	D00554	Ethinyl estradiol (USP)
D14	D00966	Tamoxifen citrate (JP18/USP)
D15	D01161	Fulvestrant (JAN/USP/INN)
D16	D02714	Everolimus (JAN/USAN/INN)
D17	D00951	Medroxyprogesterone acetate (JP18/USP)
D18	D11011	Alpelisib (JAN/USAN/INN)